Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Thrombotic risk" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Assessment of cardiac health and thrombotic risk in a patient
ActiveUS20060199239A1Reduce riskRisk of the thrombotic event is assessedOrganic active ingredientsPeptide/protein ingredientsDiseasePercent Diameter Stenosis
The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and / or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and / or atherosclerosis.
Owner:GURBEL PAUL A
Identifying coronary or soft tissue calcification
This document relates to methods and materials involved in identifying calcification (e.g., coronary calcification or soft tissue calcification) in mammals and assessing thrombotic risk in mammals. For example, methods and materials involved in using microvesicles as a marker to determine whether or not a mammal (e.g., a human) has calcification or an elevated risk of thrombosis are provided. In addition, methods and materials for determining the amount and source of microvesicles are provided.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Assessment of cardiac health and thrombotic risk in a patient
ActiveUS7381536B2Reduce riskRisk of the thrombotic event is assessedOrganic active ingredientsPeptide/protein ingredientsPercent Diameter StenosisThrombus
The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and / or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and / or atherosclerosis.
Owner:GURBEL PAUL A
Low-blood-loss micro axial-flow type artificial heart
The invention discloses a low-blood-loss micro axial-flow type artificial heart which comprises a vane wheel, a motor rotor, and a motor stator, wherein the vane wheel is arranged inside the motor rotor in an interference fit and coaxial mode, the vane wheel is placed between an entry guide vane and an exit guide vane, two flow-guiding cones with large ends of 3mm are respectively arranged on an inlet end of the entry guide vane and an outlet end of the exit guide vane, the conical degree of the flow-guide cone is 90 degrees, and the two flow-guiding cones are in symmetrical arrangement. The helical angle of each flow-guiding vane on the entry guide vane gradually reduces from 90 degrees to 30 degrees along the axial direction from the inlet end to the outlet end, and the helical angle of each flow-guiding vane on the exit guide vane 3 gradually increases from 30 degrees to 90 degrees along the axial direction from the inlet end to the outlet end. The vanes on the vane wheel and all the flow-guiding vanes are in the shape of a logarithm helical line. Shaftless drive of the vane wheel reduces thrombus risk, and the micro structure improves the ability to implant. The low-blood-loss micro axial-flow type artificial heart has the advantages of being low in hemolysis, strong in implanting ability, simple in structure, high in reliability and the like.
Owner:JIANGSU UNIV
Anti-infective, safe and efficient hemostatic aerogel and preparation method thereof
ActiveCN108421081ASimple production processEfficient production processSurgical adhesivesPharmaceutical delivery mechanismSupercritical dryingThrombus
The invention discloses anti-infective, safe and efficient hemostatic aerogel which is prepared by supercritical drying after hydrogel is prepared from 8-O-acetyl saponin methyl ester-grafted chitosan, sodium alginate, gellan gum and water; the 8-O-acetyl saponin methyl ester-grafted chitosan is prepared by grinding for 20-30 minutes under infrared light after chitosan salt is mixed with 8-O-acetyl shanzhiside methyl ester according to the mass ratio of (5-8):l; the molecular weight of the chitosan salt is 50-100 kDa, and the degree of deacetylation is 90-100 percent; the chitosan salt is at least one of hydrochloride, acetate and lactate. The 8-O-acetyl saponin methyl ester is grafted to the chitosan, the hydrogel is prepared by the coordination of the sodium alginate, the water and the gellan gum, and the aerogel is obtained by supercritical drying; the prepared hemostatic aerogel is good in swelling property, strong in adhesiveness and quick in hemostasis, difficultly enters blood to cause the thrombosis risk, has an anti-infective effect and is particularly suitable for quick hemostasis of severe bleeding such as deep acute trauma and arterial rupture.
Owner:GUANGDONG OCEAN UNIVERSITY +1
Woven vascular drug stent
The invention belongs to the field of medical apparatuses, and in particular relates to a vascular woven stent. The vascular woven stent comprises a woven stent main body and a coating, wherein the woven stent main body is constituted by metal wires having a shape memory function; and the coating comprises a drug coating bottom course and a protective top course. The vascular woven stent provided by the invention, by combining the woven stent, can effectively relieve coating falling, so that an acute thrombosis risk is reduced, stimulation to vascular walls and blood vessels is relieved, an occurrence rate of vascular restenosis is reduced, thrombogenesis is relieved, influence of patients' complications to the drug coating is relieved, and finally, product's effectiveness is improved.
Owner:LEO MEDICAL
A kind of preparation method of chitosan-agar oligosaccharide porous ball beads hemostatic material
ActiveCN106822986BHigh porosityGood swelling propertiesSurgical adhesivesPharmaceutical delivery mechanismAlcoholThrombus
The invention discloses a preparation method of a chitosan-agar oligosaccharide porous ball hemostatic material. The method comprises the following steps of: S1, preparing a chitosan-agar oligosaccharide compound solution; S2, adding a crosslinking agent 1,3-diepoxy glyceryl ether glycerinum into a compound alcohol solution, dropwise adding the chitosan-agar oligosaccharide compound solution into the compound alcohol solution containing the 1,3-diepoxy glyceryl ether glycerinum under the ultrasonic power of 130-150W, after dropwise addition, stopping ultrasonic treatment, and stirring the mixture for 30min at 600-800rpm; and S3, filtering balls, and washing, freezing and drying the balls. The hemostatic material prepared by the invention is good in biocompatibility and safe and non-toxic, can quickly accelerate blood clotting and has efficient hemostatic activity, has a certain volume, and is unlikely to enter blood to induce a thrombus risk. Meanwhile, the material has excellent wound adaptability, and is in particular suitable for bleed stopping of wounds which are deep, narrow and irregular. The preparation disclosed by the invention is simple in preparation process and easy for industrial production.
Owner:GUANGDONG OCEAN UNIVERSITY
Medicament for preventing in-stent restenosis after coronary stent implantation and preparation method
ActiveCN102872455AReduce the incidence of restenosisReduce long-term thrombosis riskHydroxy compound active ingredientsPeptide/protein ingredientsSide effectClinical efficacy
The invention discloses a medicament for preventing in-stent restenosis after coronary stent implantation and a preparation method. The medicament is prepared into 1000 parts from, by weight, 800-1200 parts of tanshinone, 200-300 parts of hirudin, 20-30 parts of camphol and borneol and 6-9 parts of musk ketone. The medicament has the advantages of effective treatment, no toxic and side effects and capabilities of decreasing occurrence rate of in-stent restenosis after coronary stent implantation, obviously improving clinical symptoms of patients and reducing long-term risks of thrombosis of the patients, and is obvious in clinical effect. The medicament provides a new choice for preventing ISR (in-stent restenosis) after coronary stent implantation.
Owner:贵州中医药大学
Protein chip for combined detection of multiple thrombus markers
PendingCN111024941ALow costRealize automated detectionDisease diagnosisBiological testingDimerFibrinogen degradation product
The invention discloses a protein chip for combined detection of multiple thrombus markers. A preparation method of the protein chip comprises the following steps: (1) black slide pretreatment; (2) antibody solution sample application; (3) a sealing process; and preparation of the protein chip. The protein chip is used for detecting concentrations of various thrombus markers, preventing and reducing thrombus risks and guiding thrombus treatment. The product disclosed by the invention is a protein chip diagnostic kit comprising six indexes of TAT (thrombin-antithrombin complex), PIC (plasmin-alpha2 anti-plasminogen complex), tPAIC (tissue-type plasminogen activator-plasminogen activation inhibition complex), TM (thrombomodulin), FDP (fibrinogen degradation product) and DD (D-dimer). The indexes are detected by using a protein chip technology for the first time, and the method has the advantages of quickness, high efficiency, simplicity, convenience, low cost and the like.
Owner:江苏三联生物工程股份有限公司
Preparation method of chitosan-agar oligosaccharide porous ball hemostatic material
ActiveCN106822986AHigh porosityGood swelling propertiesSurgical adhesivesPharmaceutical delivery mechanismAlcoholBiocompatibility Testing
The invention discloses a preparation method of a chitosan-agar oligosaccharide porous ball hemostatic material. The method comprises the following steps of: S1, preparing a chitosan-agar oligosaccharide compound solution; S2, adding a crosslinking agent 1,3-diepoxy glyceryl ether glycerinum into a compound alcohol solution, dropwise adding the chitosan-agar oligosaccharide compound solution into the compound alcohol solution containing the 1,3-diepoxy glyceryl ether glycerinum under the ultrasonic power of 130-150W, after dropwise addition, stopping ultrasonic treatment, and stirring the mixture for 30min at 600-800rpm; and S3, filtering balls, and washing, freezing and drying the balls. The hemostatic material prepared by the invention is good in biocompatibility and safe and non-toxic, can quickly accelerate blood clotting and has efficient hemostatic activity, has a certain volume, and is unlikely to enter blood to induce a thrombus risk. Meanwhile, the material has excellent wound adaptability, and is in particular suitable for bleed stopping of wounds which are deep, narrow and irregular. The preparation disclosed by the invention is simple in preparation process and easy for industrial production.
Owner:GUANGDONG OCEAN UNIVERSITY
Stent
Owner:SHANGHAI MICROPORT MEDICAL (GROUP) CO LTD
Ovarian malignant tumor patient thrombus risk prediction model modeling method and prediction device
The invention discloses an ovarian malignant tumor patient thrombus risk prediction model modeling method and prediction device, and the modeling method comprises the steps: obtaining clinical examination data of a research object; taking whether venous thromboembolism occurs or not as a dependent variable, and establishing a logistic regression model by using the clinical examination data to obtain independent prediction factors of venous thromboembolism; and establishing a column graph according to the independent prediction factors. According to the modeling method and the prediction device, the risk of venous thromboembolism of the patient with the ovarian malignant tumor is predicted through the column diagram constructed by using the clinical examination data, and a quantitative prediction result with higher accuracy can be obtained.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
Medicine eluting instrument and manufacturing method thereof
The invention relates to a medicine eluting instrument and a manufacturing method thereof. The medicine eluting instrument comprises a basal body and a medicine carrying layer, wherein the basal bodycomprises an outer surface, side surfaces and an inner surface; the medicine carrying layer contains a medicine carrier and an active medicine; the outer surface, the side surfaces and the inner surface of the basal body are covered by the medicine carrying layer; and the active medicine is only distributed on at least a part of regions covering the outer surface and the side surfaces, of the medicine carrying layer, in the thickness direction of the at least a part of the regions, the concentration of the active medicine on one side adjacent to the basal body is greater than that of the active medicine on one side away from the basal body, and the region in the inner surface of the basal body, of the medicine carrying layer does not contain the active medicine. Through the adoption of themedicine eluting instrument disclosed by the invention, the release period of the active medicine is long, and the risk of generating thrombosis is low.
Owner:BIOTYX MEDICAL (SHENZHEN) CO LTD
Use of CLEC1B for the determination of cardiovascular and thrombotic risk
The use of the single nucleotide polymorphism (SNP) of the CLEC1B gene for the identification of cardiovascular and / or thrombotic disorders or of an increased risk for developing cardiovascular and / or thrombotic disorders in a biological sample taken from an individual to be examined; the use of CLEC1B for identifying substances active in preventing and / or treating cardiovascular and / or thrombotic disorders and methods for doing so.
Owner:SANOFI AVENTIS SA
Kit for detecting contents of hirudin, bivalirudin and dabigatran in plasma
ActiveCN114703252AQuick checkAccurate detectionCompound screeningApoptosis detectionChromogenic SubstratesThrombus
The invention discloses a kit for detecting the content of hirudin, bivalirudin and dabigatran in plasma. The kit comprises a reagent R1, a reagent R2, a diluting reagent, a hirudin calibrator, a bivalirudin calibrator and a dabigatran calibrator, the R1 reagent comprises thrombin, a first buffer solution and a first auxiliary material, the R2 reagent comprises a chromogenic substrate, a second buffer solution and a second auxiliary material, and the diluting reagent comprises a third buffer solution and a third auxiliary material; the hirudin calibrator comprises hirudin, the bivalirudin calibrator comprises bivalirudin, and the dabigatran calibrator comprises dabigatran; the reagent is high in sensitivity and good in stability, the content of hirudin, bivalirudin and dabigatran in plasma can be rapidly and accurately detected, detection of the medication conditions of hirudin, bivalirudin and dabigatran can be achieved at the same time, the drug residue concentration of a patient can be rapidly and effectively known, and the bleeding or thrombus risk in the body of the patient can be accurately evaluated.
Owner:SHENZHEN DYMIND BIOTECH
Freezing defibrillator for cardiac surgery
The invention discloses a freezing defibrillator for cardiac surgery, which belongs to the technical field of medical instruments, and aims to solve the problems that tissues are easily burnt, disability is caused and thrombus risks are caused in an electric shock treatment method in the prior art. The freezing defibrillator comprises a freezing airflow guide pipe, the freezing airflow guide pipeis of a cylindrical structure, and an opening in one end of the freezing airflow guide pipe serves as an outflow opening; an inflow adjusting structure is connected with the other end of the freezingairflow guide pipe, the inflow adjusting structure is connected with external freezing air supply equipment through a flow guide pipe, and the amount of freezing air flowing into the freezing airflowguide pipe is adjusted through the inflow adjusting structure; a backflow body is coaxially arranged outside the freezing airflow guide pipe; wherein a freezing cap is detachably connected with the end, close to the flow outlet of the freezing airflow guide pipe, of the backflow body in a sealed mode, the interior of the freezing cap is communicated with the interior of the freezing airflow guidepipe through the flow outlet of the freezing airflow guide pipe, and freezing air in the freezing cap is transmitted to the end, away from the freezing cap, of the backflow body from the end close tothe freezing cap.
Owner:JILIN UNIV
Pipe material for preparing stent and its preparation method, stent and its preparation method
ActiveCN107693854BImprove mechanical propertiesEffective Radial Support ForceStentsSurgeryFiberFatigue fractures
Owner:上海发微医用材料有限公司
Thrombotic episode risk assays using oxidized phospholipids
InactiveUS7011956B1Microbiological testing/measurementBiological testingLipid formationThrombotic episodes
An assay to assess thrombotic risk in which oxidized lipids comprising phospholipids are utilized as a membrane source in a clotting assay and the results compared to an assay in which unoxidized phospholipid is used as a membrane source in the presence and absence of activated protein C (“APC”). The assay can monitor for the presence of antibodies in the patient which interfere specifically with the anticoagulant function of APC in an oxidation dependent or independent manner. This can indicate the propensity of the patient to experience episodes of vein thrombosis or arterial thrombosis.
Owner:OKLAHOMA MEDICAL RES FOUND
Heart valve
The invention relates to a heart valve which comprises a valve stent and a tying rope, wherein the valve stent comprises a main body stent, a skirt stent and a fixing part; the skirt stent and the fixing part are separately arranged on the main body stent; and the tying rope is detachably connected with the main body stent. In the operation process, after it is ensured that the fixing part is fixedly connected with heart tissue through push testing, the tying rope can be dissociated from the valve stent, and thus the risk of thrombi caused if the tying rope is retained in a left ventricle canbe avoided.
Owner:LIFETECH SCIENTIFIC (SHENZHEN) CO LTD
Double-vena cava port capable of preventing thrombosis and preventing secondary infection
ActiveCN108785791BSpeed up entryIncrease the needle entry pointOrganic active ingredientsInfusion devicesAnticoagulant AgentThrombus
The invention discloses a double-compartment venous port access as well as a using method of venous transfusion and drug storage sustained release thereof. The venous port access comprises an infusioncatheter and a cylindrical access body which is formed by medical silica gel, wherein the access body comprises a cavity; two ends of the access body are of hemispherical structure; the cavity is provided with a diaphragm, so that the cavity is divided into two compartments; the diaphragm is provided with pores by which liquid can permeate; and the infusion catheter is connected to one end of theaccess body and communicates with one of the compartments. The method comprises the following steps: implanting the double-compartment venous port access into a human body; penetrating an intravenousinjection into the compartment which communicates with the infusion catheter and conducting infusion; penetrating a fine-needle syringe into the other compartment of the venous port access to injectan anticoagulant or an antibacterial agent, so that the anticoagulant or the antibacterial agent is slowly released towards tissues around the compartment and / or the venous port access communicating with the infusion catheter via the diaphragm. The double-compartment venous port access is convenient for surgical implantation, and the venous port access is small in surgical incision and convenientfor puncture and infusion operations; and moreover, risks of thrombus and secondary infection can be effectively reduced.
Owner:谢博宇
Isolating culture method and application of human umbilical cord mesenchymal stem cells
InactiveCN112980784AIncrease vitalityReduce expressionPharmaceutical delivery mechanismMammal material medical ingredientsUmbilical cord tissueReceptor
The invention discloses an isolating culture method and application of human umbilical cord mesenchymal stem cells. The isolating culture method comprises the following steps: separating umbilical cord Wharton's jelly from umbilical cord tissues; adding a serum-free culture medium containing melatonin into the umbilical cord Wharton's jelly, cutting the umbilical cord Wharton's jelly into pieces, placing the umbilical cord Wharton's jelly at the concentration of O2 of 1.5-2.5% for adherent culture, when the adherent cell confluence is 50-80%, discarding fragments of the umbilical cord Wharton's jelly and continuing to culture; and after the culture is finished, digesting and dispersing the cells, and then centrifuging and seeding for subculture to obtain the human umbilical cord mesenchymal stem cells. According to the isolating culture method, the harvested human umbilical cord mesenchymal stem cells can generate more immunomodulatory cell factors and chemotactic receptors, the activity of the human umbilical cord mesenchymal stem cells harvested after cryopreservation and recovery is higher, and the expression of stem cell tissue factors can be reduced, so that the thrombus risk caused by the process of stem cell intravenous injection is reduced.
Owner:贾在美
A kind of high-efficiency hemostatic sponge and preparation method thereof
ActiveCN107041965BSimple preparation processEasy to process productionSurgical adhesivesPharmaceutical delivery mechanismDeep woundsThrombus
The invention discloses efficient hemostatic sponge. The efficient hemostatic sponge is prepared from the following raw materials in percentage by mass: 35%-60% of chitosan, 0.1%-0.5% of thrombin, 1%-3% of polyglutamic acid, 9% of sodium chloride, 20%-35% of sodium alginate, 5%-15% of sodium hyaluronate and 1%-5% of calcium chloride. The efficient hemostatic sponge comprises a surface layer and an inner layer, wherein the surface layer is an antibacterial hemostatic layer containing chitosan, thrombin, polyglutamic acid and sodium chloride; and the inner layer is a gel layer containing sodium alginate, sodium hyaluronate and calcium chloride. The inner layer of the hemostatic sponge is in direct contact with a wound and is capable of absorbing moisture in blood to form gel to block the wound so as to realize primary hemostasis; concentrated blood penetrates through the gel layer to enter the surface layer so as to realize further hemostasis with the combined action of thrombin and chitosan; immobilized thrombin on an outer layer in the hemostatic sponge is capable of enhancing the stability, preserves efficient hemostatic activity and is unlikely to enter blood to cause a thrombus risk; and the efficient hemostatic sponge is particularly applicable to rapid hemostasis of serious bleeding caused by deep wounds, arteriorrhexis and the like.
Owner:GUANGDONG OCEAN UNIVERSITY
Steep pulse electric field ablation control system
PendingCN114869453AIncrease the electric field strengthFast pulse frequencySurgical instruments for heatingElectrical field strengthThrombus
The invention discloses a steep pulse electric field ablation control system which comprises a pulse electric field control part and an ultrasonic imaging part, and the pulse electric field control part and the ultrasonic imaging part carry out data interaction through a communication interface. According to the invention, a steep pulse electric field with high electric field intensity, fast pulse frequency and short pulse width can be provided. The steep pulse electric field of non-thermal energy ablation only causes irreversible electroporation to cells and does not cause protein denaturation, so that the thrombus risk in the ablation process is reduced to a great extent. Besides, the pulse sequence of any combination can be accurately controlled to be output, so that a time window of the cardiac refractory period is effectively adapted, and the adverse effect of the ablation process on the effective refractory period is avoided.
Owner:SHANGHAI GOLDEN LEAF MED TEC
Novel nano fiber vascular stent material with double-drug loading and staged slow release functions and preparation method of thereof
The invention discloses a novel nano fiber vascular stent material with double-drug loading and staged slow release functions and a preparation method thereof. Immunoglobulin lgG antibodies coupled tothe outer layer of the stent material stimulate cells to form epithelial tissues, so that the risk of thrombus formation is reduced; due to decomposition of polylactic acid on the outer layer of thescaffold, penicillin loaded on polylactic acid is slowly released, and division and growth of abnormal cells are inhibited. Due to decomposition of a nitric oxide donor combined with chitosan on the inner layer of the stent, nitric oxide free radicals are slowly released so as to expand blood vessels and inhibit tumor growth. The stent material has double drugs: loaded penicillin and nitric oxideand has a function of slowly releasing drugs in different stages layer by layer; the stent is expected to serve as a novel multifunctional vascular stent in clinic and can be implanted into coronary artery blood vessels of a patient, and multiple postoperative treatment effects of supporting focus blood vessels, reducing thrombus risks, inhibiting cytopathy, expanding blood vessels through free radicals, inhibiting tumor growth and the like are achieved.
Owner:QINGDAO UNIV
Nanofibrous vascular stent material with dual drug loading and stepwise sustained release function and preparation method thereof
The invention discloses a novel nanofiber vascular stent material with dual-drug loading and step-by-step slow-release functions and a preparation method thereof. The immunoglobulin IgG antibody coupled to the outer layer of the stent material stimulates cells to form epithelial tissue and reduces the formation of thrombus risk; due to the decomposition of polylactic acid in the outer layer of the scaffold, the penicillin loaded by it is slowly released, which inhibits the division and growth of abnormal cells; due to the decomposition of the nitric oxide donor bound to chitosan in the inner layer of the scaffold, the nitric oxide is slowly released freely base, to dilate blood vessels and inhibit tumor growth; the scaffold material has the function of loading penicillin and nitric oxide dual drugs, and releases drugs layer by layer, and is expected to be clinically used as a new type of multifunctional vascular stent implanted in the patient's heart Coronary arteries can achieve many postoperative therapeutic effects such as supporting the lesion blood vessels, reducing the risk of thrombus, inhibiting cytopathy, expanding blood vessels by free radicals, and inhibiting tumor growth.
Owner:QINGDAO UNIV
Support
PendingCN111789704AReduce wall thicknessImprove extrusion resistanceStentsVascular endotheliumThrombus
The invention relates to a support. The support comprises a plurality of supporting unit loops, wherein each supporting unit loop comprises a plurality of columns, a plurality of proximal end turningparts and a plurality of distal end turning parts, the proximal end turning parts and the distal end turning parts are alternately connected to proximal ends and distal ends of the columns so as to enable the supporting unit loops to form a closed structure, and the proximal end turning parts and the distal end turning parts are separately provided with concave cambered surfaces and convex cambered surfaces which are contrary to each other. According to the support disclosed by the invention, through improving structures of the proximal and distal end turning parts of the supporting unit loopsof the support, higher extruding resistance is obtained, so that the support is not easily collapsed by pressure and maintains good supporting performance on a vascular wall; and in case of maintaining a sufficient supporting force, the wall thickness of the support with such a structure can be reduced as much as possible, and the probability of occurrence of thrombosis and vascular endothelium delayed healing caused by support wall thickness influence is lowered.
Owner:SHANGHAI MICROPORT MEDICAL (GROUP) CO LTD
Multifunctional bleeding arresting nanoparticles with low thrombosis risk, preparation method therefor and application of multifunctional bleeding arresting nanoparticles
ActiveCN112245406AEfficient hemostasisSequential regulation of coagulation statusOrganic active ingredientsPharmaceutical non-active ingredientsThrombusAntiplatelet drug
The invention relates to the technical field of medicines and discloses multifunctional bleeding arresting nanoparticles with low thrombosis risk. The multifunctional bleeding arresting nanoparticlesare prepared from the following ingredients in parts by weight: 1-4 parts of polypeptide with positive charges and 2-4 parts of prodrug of antiplatelet drugs. The invention further provides a preparation method for the multifunctional bleeding arresting nanoparticles with low thrombosis risk. The invention further provides application of the multifunctional bleeding arresting nanoparticles with low thrombosis risk. The multifunctional bleeding arresting nanoparticles can be used for efficiently arresting bleeding, resisting infection and promoting restoration and can be used for inhibiting a hypercoagulative state of blood in an organism and lowering the risk of thrombosis.
Owner:CHONGQING UNIV OF TECH +1
Medicament for preventing in-stent restenosis after coronary stent implantation and preparation method
ActiveCN102872455BReduce the incidence of restenosisReduce long-term thrombosis riskHydroxy compound active ingredientsPeptide/protein ingredientsCoronary arteriesThrombus
Owner:贵州中医药大学
Human venous thrombosis risk gene polymorphism detection kit, process and application
PendingCN114672548AEasy to identifyHigh sensitivityMicrobiological testing/measurementDNA/RNA fragmentationFluoProbesThrombus
The invention belongs to the technical field of polymorphism detection, and particularly relates to a human venous thrombosis risk gene polymorphism detection kit and process and application. PAI-1 4G / 5G and THBDc.-151Ggt are detected at the same time; t, and PROC 565Cgt; the invention discloses a kit for detecting the polymorphism of genes such as T (rs146922325) and PROC c.574576del, the kit comprises a reagent A, a reagent B, a positive quality control A, a positive quality control product B and a negative control, and the reagent A comprises a PAI-1 4G / 5G wild type and THBD c.-151Ggt; a specific primer, a common probe and a paired primer of the T wild type, PROC 565Cgt; t upstream and downstream primers, and PROC 565Cgt; according to the kit, a PCR-fluorescent probe method is adopted, a completely closed system is adopted for amplification reaction and detection, false positive caused by aerosol pollution is avoided, and the kit is simple in operation method, short in detection period, low in detection cost and good in sensitivity and specificity.
Owner:华捷生物科技(青岛)有限公司
PICC thrombus risk prediction method based on machine learning
PendingCN113270193AWill not change the distributionAvoid impacts on forecast accuracyHealth-index calculationKernel methodsPharmacy medicineMedicine
The invention discloses a PICC thrombus risk prediction method based on machine learning, and the method comprises the steps: collecting 30 features affecting PICC thrombus of each patient, and carrying out the filling of the missing values of the features; preprocessing the filled features; constructing a plurality of risk prediction models based on machine learning, and respectively calculating an F1 index, an accuracy rate, a recall rate and an AUC of each risk prediction model; determining the effect of each risk prediction model according to the F1 index, the accuracy rate, the recall rate and the AUC of each risk prediction model; selecting two risk prediction models with optimal effects; and based on the AUC values of the two risk prediction models with the optimal effects and the probability of predicting the AUC values to be 1, fusing the two risk prediction models with the optimal effects, and outputting a PICC thrombus risk prediction result. Precise recognition of thrombus occurrence risks is achieved, treatment or nursing measures are taken in advance to conduct medicine or physical intervention on high-risk patients, and therefore the probability of thrombus occurrence of the patients is reduced.
Owner:JIANGSU UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com